Literature DB >> 11356908

Intracellular localization of the radiation enhancer motexafin gadolinium using interferometric Fourier fluorescence microscopy.

K W Woodburn1.   

Abstract

Motexafin gadolinium (MGd) is a unique therapeutic agent that localizes in cancer cells and increases tumor response to ionizing radiation and certain chemotherapeutics. The in vitro intracellular localization, accumulation, and retention of MGd in murine EMT6 mammary sarcoma and Rif-1 fibrosarcoma cell lines were studied using interferometric Fourier fluorescence microscopy. MGd cellular uptake was semiquantified using its characteristic fluorescence emission band centered at 758 nm. Colocalization studies were performed using mitochondrial, endoplasmic reticulum, Golgi apparatus, nuclear, and lysosomal fluorescent organelle probes, and verified using interferometric Fourier spectroscopy. Cellular uptake was gradual and increased significantly with incubation time. MGd localized primarily within the lysosomes and endoplasmic reticulum, and to a lesser extent within the Golgi apparatus and mitochondria. Mitochondrial staining was increased in media without serum. No nuclear uptake was detected in the Rif-1 cells, but after 48 h nuclear uptake was observed in 15% of EMT6 cells. These results indicated that MGd accumulates within cytoplasmic compartments. The sustained intracellular localization of MGd may, in part, account for its unique radiation and chemotherapy enhancement properties. Interferometric Fourier fluorescence microscopy is a potentially powerful tool in delineating and verifying localization sites of therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11356908

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  An adhesion-based method for plasma membrane isolation: evaluating cholesterol extraction from cells and their membranes.

Authors:  Ludmila Bezrukov; Paul S Blank; Ivan V Polozov; Joshua Zimmerberg
Journal:  Anal Biochem       Date:  2009-07-22       Impact factor: 3.365

2.  Porphyrinoid Drug Conjugates.

Authors:  Jonathan F Arambula; Jonathan L Sessler
Journal:  Chem       Date:  2020-07-09       Impact factor: 22.804

3.  Texaphyrins and water-soluble zinc(II) ionophores: development, mechanism of anticancer activity, and synergistic effects.

Authors:  Christian Preihs; Darren J Magda; Jonathan L Sessler
Journal:  Bioinorg React Mech       Date:  2013-12-01

4.  In vivo imaging with a cell-permeable porphyrin-based MRI contrast agent.

Authors:  Taekwan Lee; Xiao-an Zhang; Shanta Dhar; Henryk Faas; Stephen J Lippard; Alan Jasanoff
Journal:  Chem Biol       Date:  2010-06-25

5.  Chiral porphyrazine near-IR optical imaging agent exhibiting preferential tumor accumulation.

Authors:  Evan R Trivedi; Allison S Harney; Mary B Olive; Izabela Podgorski; Kamiar Moin; Bonnie F Sloane; Anthony G M Barrett; Thomas J Meade; Brian M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-23       Impact factor: 11.205

Review 6.  Motexafin gadolinium injection for the treatment of brain metastases in patients with non-small cell lung cancer.

Authors:  Sayana R Thomas; Deepak Khuntia
Journal:  Int J Nanomedicine       Date:  2007

7.  MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain.

Authors:  Genevieve N Wu; Judith M Ford; Jeffry R Alger
Journal:  J Neurooncol       Date:  2006-03-18       Impact factor: 4.130

8.  The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial.

Authors:  Andrew M Evens; William G Spies; Irene B Helenowski; David Patton; Stewart Spies; Borko D Jovanovic; Sarah Miyata; Elizabeth Hamilton; Daina Variakojis; Jun Chen; Louie Naumovski; Steven T Rosen; Jane N Winter; Richard A Miller; Leo I Gordon
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

9.  Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents.

Authors:  Grégory Thiabaud; Guangan He; Sajal Sen; Kathryn A Shelton; Wallace B Baze; Luke Segura; Julie Alaniz; Ruben Munoz Macias; Greg Lyness; Alan B Watts; Hyun Min Kim; Hyunseung Lee; Mi Young Cho; Kwan Soo Hong; Rick Finch; Zahid H Siddik; Jonathan F Arambula; Jonathan L Sessler
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-16       Impact factor: 11.205

10.  Motexafin gadolinium enhances the efficacy of aminolevulinic acid mediated-photodynamic therapy in human glioma spheroids.

Authors:  Steen J Madsen; Marlon S Mathews; Even Angell-Petersen; Chung-Ho Sun; Van Vo; Rogelio Sanchez; Henry Hirschberg
Journal:  J Neurooncol       Date:  2008-09-06       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.